Alefacept treatment for chronic plaque psoriasis.
Biologic agents were introduced during the past decade as a new class of treatments for chronic psoriasis. These agents provide therapeutic alternatives to traditional topical and systemic therapies. Alefacept, the first such biologic agent, was approved by the US FDA in January 2003 for the treatment of chronic plaque psoriasis. This review will discuss data from clinical trials that have provided new insights into the efficacy, safety, and cost effectiveness of alefacept as a treatment for psoriasis.
Dunn
L K
LK
Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, US.
Feldman
S R
SR
D000077944:Alefacept; D002908:Chronic Disease; D003365:Costs and Cost Analysis; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D011565:Psoriasis / Q000188:drug therapy* / Q000191:economics; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D016896:Treatment Outcome
D003879:Dermatologic Agents; D011993:Recombinant Fusion Proteins; D000077944:Alefacept